Progestogen-only Injectables

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

Please read this guidance document in conjunction with any relevant clinical statements for this topic:

FSRH CEU Statement: Response to new study by Meaidi et al (2023) Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs (September 2023)

FSRH Response to new study on use of CHC and POC and breast cancer risk (March 2023)

FSRH CEU Response to published study: Maternal use of hormonal contraception and risk of childhood leukemia: a nationwide, populate-based cohort study (September 2018)

FSRH CEU Statement to published systematic review: The relationship between progestin hormonal contraception and depression: a systematic review (March 2018)

FSRH CEU Statement: Response to Study Contemporary Hormonal Contraception and the Risk of Breast Cancer (December 2017)

FSRH CEU Statement: Contraception and Weight Gain (August 2019)

The CEU supports the self administration of Sayana Press® because of its potential benefits to women and services. It offers women greater choice and more autonomy over their contraception and fertility.

Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).